EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT

/PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced that one-year results on patients treated in the single-arm, prospective, global,...

Related Keywords

France ,London ,City Of ,United Kingdom ,Didier Tchetche ,Volker Rudolph ,Philipp Lurz ,Konstantinos Spargias ,Niklas Schofer ,Bernardj Zovighian ,Clinique Pasteur ,Edwards Lifesciences ,Michael Young ,Instagram ,Linkedin ,Twitter ,Exchange Commission ,Youtube ,Edwards Lifesciences Corporation ,Securities Exchange ,Facebook ,Tricuspid Valve Repair ,Roll In Cohort ,Breaking Trial Presenter ,Tricuspid Annular Reduction ,Randomized Comparison ,Transcatheter Edge To Repair Devices ,Degenerative Mitral Regurgitation ,Prohibitive Surgical Risk Patients ,Prospective Registry ,Transcatheter Edge To Repair ,Transcatheter Mitral Repair ,Tricuspid Regurgitation ,Six Month Follow Up ,Securities Act ,Securities Exchange Act ,Annual Report ,Quarterly Reports ,